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See related research by Slowinski et al., http://www.ccforum.com/content/19/1/349The recently published Liver Citrate Anticoagulation
Threshold (L-CAT) trial convincingly showed that con-
tinuous renal replacement therapy with regional citrate
anticoagulation (CRRT-RCA) was safe and effective in
patients with severely impaired liver function. Striking
findings were a relatively low incidence of acid–base dis-
orders and a markedly long 72-h filter survival [1].
Nonetheless, we would like to comment on two import-
ant metabolic issues. First, the low (2 %) incidence of
severe metabolic alkalosis, defined as a pH >7.55, is
probably highly underestimated. Indeed, we recently
evaluated the occurrence of metabolic alkalosis defined
either as a pH >7.50 or as an apparent strong ion differ-
ence (SIDa) >45 mmol/L according to the Stewart-Figge
methodology [2] in patients undergoing CRRT-RCA* Correspondence: Patrick.Honore@az.vub.ac.be
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rate solution. Calculating SIDa revealed a ninefold in-
crease in the percentage of metabolic alkalosis [3]!
Accordingly, applying the SIDa approach likely will
uncover a substantially higher incidence of severe meta-
bolic alkalosis in the L-CAT patients. Second, the L-
CAT investigators attributed the long filter lifespan to a
more automated fine-tuning of citrate and calcium dos-
ing. However, we recently demonstrated that keeping
post-filter ionized calcium (iCa) within tight limits (i.e.,
0.2–0.3 mmol/L) during CRRT-RCA resulted in a 72-h
filter survival comparable with that observed in the L-
CAT trial [4]. Post-filter iCa levels in all L-CAT trial
groups were within the same range and thus may have
accounted for a better preserved filter patency.We agree with Honoré et al. that the use of the Stewart-
Figge approach probably would have discovered a higher
incidence of alkalosis in the study population of the
L-CAT study [1]. However, in clinical practice as well
as in other studies investigating RCA the Henderson
and Hasselbalch approach is used. For practical rea-
sons in this multicenter trial and to allow better com-
parisons with other studies, we decided to use the
latter approach in the L-CAT study.
The major outcome parameter for safety in the L-CAT
study was the incidence of severe acidosis (pH ≤7.2)
or alkalosis (pH ≥7.5) in patients with different de-
grees of liver failure. Most important, we found no
significant difference between these groups and this
was true not only for pH, but also for bicarbonate
concentration. Thus, even if the overall incidence ofalkalosis might have been slightly different using the
Stewart-Figge approach, most probably no differences
between the study groups would have been detected
this way.
Regarding the problem of metabolic alkalosis during
RCA, it is of note that other colleagues, i.e., Oudemanns-
van Straaten et al. [5], reported a significantly higher inci-
dence of metabolic alkalosis (bicarbonate >30 mmol/L) in
patients treated with conventional bicarbonate containing
solutions in systemic anticoagulated continuous veno-
venous hemofiltration (CVVH; 26 %) compared with
those who were treated with RCA-CVVH (9 %). This ob-
servation clearly shows an urgent need to analyze different
protocols in CRRT with regard to their efficiency to con-
trol acid–base state.
Of note, we agree that keeping ionized calcium con-
centrations within the extracorporeal circuit in tight
limits is the most important task in terms of avoiding fil-
ter clotting in RCA-CRRT. In vitro data showed that iCais distributed under the terms of the Creative Commons Attribution 4.0
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sufficient anticoagulation [6].
Discussing filter lifetime as efficacy endpoint, the L-
CAT study showed a filter patency rate of >90 % after
72 hours if treatment stops not caused by clotting were
censored. Thus, the filter clotting rate has decreased
continuously compared with earlier publications of
Morgera et al. [7] and Kalb et al. [8], which used exactly
the same RCA protocol. Obviously, with increasing ex-
perience and training of staff, clotting events can now-
adays be avoided almost completely. This way, safe and
effective CRRT can be applied and delivery failure is
avoidable.
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